Back to Gastroenterology


Non-Alcoholic Steatohepatitis & Non-Alcoholic Fatty Liver Disease

Metabolic Dysfunction-associated Steatotic Liver Disease & Metabolic Dysfunction-associated Steatohepatitis Market Research

What is Metabolic Dysfunction-associated Steatotic Liver Disease (MASH) & Metabolic Dysfunction-associated Steatohepatitis (MASLD)?

Metabolic Dysfunction-associated Steatotic Liver Disease (MASH) is an advanced form of Metabolic Dysfunction-associated Steatohepatitis (MASLD). MASLD is caused when fat builds up in the liver, causing symptoms such as fatigue and abdominal discomfort, though generally speaking, it can be difficult to diagnose until it has progressed, as it can be a silent disease. As the disease progresses into MASH, patients may have more distinctive symptoms, such as loss of appetite, weight loss, itchy skin, confusion, and jaundice. Patients may also find that they bruise and bleed easily. MASLD manifests to MASH as the fat in the liver builds up, causing inflammation and scarring, or fibrosis, to the liver. If fibrosis progresses, it can lead to a condition called cirrhosis, in with the liver is irreparably damaged; the condition can be life-threatening. Besides potential new treatments that may be on the horizon, physicians recommend lifestyle changes in order to slow the disease’s progression. These changes include: reducing/eliminating the consumption of alcohol (as alcohol can become a contributing factor), maintaining a healthy diet, treating underlying conditions (such as hypothyroidism), and losing weight for patients who may be overweight.

Spherix Global Insights – Gastroenterology – MASH & MASLD

Spherix Global Insights’ Gastroenterology therapeutic team is a leading provider of independent MASH & MASLD market research, insights, business intelligence & advisory services.

Spherix’s studies publishing this year covering MASH & MASLD include:

• Market Dynamix™: MASLD/MASH (US)
• Launch Dynamix: Rezdiffra (Madrigal) in MASLD/MASH (US)
• Patient Chart Dynamix™: MASLD/MASH (US)*

Spherix’s Market Dynamix™ service includes analysis of markets anticipated to experience a paradigm shift within the next three to five years. Its insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.

Spherix’s Launch Dynamixservice consists of two parts: monthly KPI tracking and quarterly deep dives. Monthly KPIs provide monthly benchmarking of newly launched products for the first eighteen months of commercial availability, and quarterly deep dive reports covering promotional activity, barriers to uptake, and patient types being identified for the launch brand.

Patient Chart Dynamix™ is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits. Insights reveal the “why” behind treatment decisions, include year over year trending to quantify key aspects of market evolution, and integrate specialists’ attitudinal & demographic data to highlight differences between stated and actual treatment patterns.

Follow us for gastroenterology industry news, insights & analysis:

For Guests & Current Clients

For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here:


Get more information on Irritable Bowel Syndrome Coverage